Contract Research Organizations (CROs) provide support to thepharmaceutical, biotechnology and related industries through outsourcedresearch and development services that span drug discovery, preclinicalresearch, clinical research, clinical trial management, commercialization, andpharmacovigilance.
The Indian CRO market is attractive, and it is one of themost attractive outsourcing global locations. India is offering a great sourceof well educated (including higher degrees), well trained, and English fluentlabor. On top of that an average PhD will cost 85% less in India than compared tothe US. India has a big and extremely diverse genetic pool to adequately fit pharmaceuticalclinical trials. On a federal level, India has divested in internal andexternal support to promote biotechnology and pharmaceutical development (i.e.
regulatoryauthorities such as Director Controller General of India (DCGI), Indian Councilof Medical Research (ICMR), Directorate General of Foreign Trade (DGFT),Department of Biotechnology (DBT) to create an amenable climate for research inIndia 2), and on the State Level Tax discounts, and Hi (Bio) Techparks development. Another predictor to the attractiveness of CROs in India,was the global growth of CROs, that in the early 2000 was at staggering 100%,and by 2010 India’s CRO were to be 20% of the global CORs market. India has become increasingly important in theglobal pharmaceutical supply chain and hence incentivizing the engagement ofIndian pharmaceutical players in research and related manufacture has resultedin contract research and manufacturing services (CRAMS) emerging as one of thefastest growing segments in the country (Biocon 2017 annual report 1).Today, India is becoming even more favorable CRO marketdestination. The leading reason being; India’s alignment of global guidelinesand IP rights, offering (even more than a decade ago) educated and accessiblelabor, low operational cost (driven by low labor costs), great source of largelyavailable hospitals, diverse types of climatic conditions, and diverse ethnicpool thus enabling diverse sample for clinical trials 2.